HRP20050184B1 - Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima - Google Patents

Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Info

Publication number
HRP20050184B1
HRP20050184B1 HRP20050184AA HRP20050184A HRP20050184B1 HR P20050184 B1 HRP20050184 B1 HR P20050184B1 HR P20050184A A HRP20050184A A HR P20050184AA HR P20050184 A HRP20050184 A HR P20050184A HR P20050184 B1 HRP20050184 B1 HR P20050184B1
Authority
HR
Croatia
Prior art keywords
combination
alkyl phosphocholines
phosphocholines
alkyl
antitumor medicaments
Prior art date
Application number
HRP20050184AA
Other languages
English (en)
Inventor
Jürgen Engel
Günther Eckhard
Herbert Sindermann
Original Assignee
Æterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Æterna Zentaris Gmbh filed Critical Æterna Zentaris Gmbh
Publication of HRP20050184A2 publication Critical patent/HRP20050184A2/hr
Publication of HRP20050184B1 publication Critical patent/HRP20050184B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Izum se odnosi na uporabu alkil fosfoholina u kombinaciji s protutumorskim lijekovima za liječenje benignih i malignih tumorskih bolesti u ljudi i sisavaca. Alkil fosfoholini se mogu koristiti u novoj kombinaciji s jednim ili nekoliko odobrenih citostatika. Poželjni alkil fosfoholini predstavljeni su u formuli II.
HRP20050184AA 2002-07-30 2005-02-25 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima HRP20050184B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39961502P 2002-07-30 2002-07-30
PCT/EP2003/008346 WO2004012744A1 (de) 2002-07-30 2003-07-29 Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten

Publications (2)

Publication Number Publication Date
HRP20050184A2 HRP20050184A2 (en) 2005-04-30
HRP20050184B1 true HRP20050184B1 (hr) 2014-04-11

Family

ID=31495746

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050184AA HRP20050184B1 (hr) 2002-07-30 2005-02-25 Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima

Country Status (27)

Country Link
US (3) US8389497B2 (hr)
EP (2) EP2301551A1 (hr)
JP (1) JP2005535688A (hr)
KR (3) KR20130016413A (hr)
CN (1) CN1302780C (hr)
AR (1) AR040717A1 (hr)
AT (1) ATE516036T1 (hr)
AU (2) AU2003253350B2 (hr)
BR (1) BR0313048A (hr)
CA (1) CA2493023C (hr)
CY (1) CY1111902T1 (hr)
DK (1) DK1545553T3 (hr)
ES (1) ES2369535T3 (hr)
HK (1) HK1080751A1 (hr)
HR (1) HRP20050184B1 (hr)
IL (1) IL166329A (hr)
MX (1) MXPA05001203A (hr)
NO (1) NO335196B1 (hr)
NZ (1) NZ538428A (hr)
PL (1) PL375493A1 (hr)
PT (1) PT1545553E (hr)
RU (1) RU2005105693A (hr)
SI (1) SI1545553T1 (hr)
TW (1) TWI332007B (hr)
UA (1) UA82322C2 (hr)
WO (1) WO2004012744A1 (hr)
ZA (1) ZA200500453B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005105693A (ru) 2002-07-30 2005-07-10 Центарис ГмбХ (DE) Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
AR058397A1 (es) * 2005-12-19 2008-01-30 Zentaris Gmbh Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos
UA99434C2 (ru) * 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
MX2010001244A (es) * 2007-07-30 2010-08-31 Ardea Biosciences Inc Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos.
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942639A (en) * 1991-07-04 1999-08-24 Asta Medica Aktiengesellschaft Process for the preparation of alkylphosphocholines and the production thereof in pure form
ES2086026T3 (es) * 1991-07-04 1996-06-16 Asta Medica Ag Farmaco con efecto antineoplasico que contiene como sustancia activa (2-(n-metil-piperidino)-etil)-fosfato de octadecilo y procedimiento para su preparacion.
US6172050B1 (en) * 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
JP3079993B2 (ja) * 1996-03-27 2000-08-21 日本電気株式会社 真空マイクロデバイスおよびその製造方法
DE19650778C2 (de) * 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
HUP0004363A3 (en) 1998-01-22 2002-12-28 Zentaris Gmbh Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis
JP2002532553A (ja) 1998-12-21 2002-10-02 インケイサ．ソシエダ アノニマ 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
EP1370270B1 (en) * 2001-03-23 2009-12-02 Shire Canada Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
WO2003005522A1 (es) 2001-07-04 2003-01-16 Acuna Arturo Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica.
RU2005105693A (ru) 2002-07-30 2005-07-10 Центарис ГмбХ (DE) Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний
WO2006081452A2 (en) 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
UA99434C2 (ru) 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
WO2003055522A1 (en) * 2002-01-02 2003-07-10 Pharmacia Italia Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
WO2005000318A2 (en) * 2003-06-23 2005-01-06 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERKOVIC D ET AL: "The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells." LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND DEC 1997, Bd. 11, Nr. 12, Dezember 1997 (1997-12),2079-2086 str. *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; Februar 1991 (1991-02) SHOJI M ET AL: "Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells." Database accession no. NLM2051897 XP002256716 & LIPIDS. UNITED STATES FEB 1991, Bd. 26, Nr. 2, Februar 1991 (1991-02), 145-149 str. *
GEORGIEVA MILKA C ET AL: "Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells." CANCER LETTERS. IRELAND 28 AUG 2002, Bd. 182, Nr. 2, 28. August 2002 (2002-08-28), 163-174 str. *
HILGARD P ET AL: "Heterocyclic alkylphospholipids with an improved therapeutic range." ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1996, Bd. 416, 1996,157-164 str. *
SPRUSS T ET AL: "ANTITUMOUR ACTIVITY OF MILTEFOSINE ALONE AND AFTER COMBINATION WITHPLATINUM COMPLEXES ON MXT MOUSE MAMMARY CARCINOMA MODELS" JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, Bd. 119, Nr. 3, 1993,142-149 str. *
STEKAR J ET AL: "Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide." EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990) ENGLAND 1995, Bd. 31A, Nr. 3, 1995, 372-374 str. *

Also Published As

Publication number Publication date
BR0313048A (pt) 2005-06-14
CA2493023A1 (en) 2004-02-12
IL166329A0 (en) 2006-01-15
SI1545553T1 (sl) 2011-09-30
US20100189784A1 (en) 2010-07-29
IL166329A (en) 2012-08-30
KR20110102485A (ko) 2011-09-16
PT1545553E (pt) 2011-09-12
RU2005105693A (ru) 2005-07-10
ATE516036T1 (de) 2011-07-15
CN1671397A (zh) 2005-09-21
HRP20050184A2 (en) 2005-04-30
KR101066804B1 (ko) 2011-09-22
US8389497B2 (en) 2013-03-05
MXPA05001203A (es) 2005-06-08
KR20130016413A (ko) 2013-02-14
US8551977B2 (en) 2013-10-08
HK1080751A1 (en) 2006-05-04
DK1545553T3 (da) 2011-09-12
EP1545553A1 (de) 2005-06-29
US8507710B2 (en) 2013-08-13
US20040097470A1 (en) 2004-05-20
KR20050026028A (ko) 2005-03-14
TWI332007B (en) 2010-10-21
NO20051040L (no) 2005-02-25
AU2003253350A1 (en) 2004-02-23
AU2003253350B2 (en) 2008-06-26
AU2008203060B2 (en) 2011-04-21
CA2493023C (en) 2012-01-31
TW200404073A (en) 2004-03-16
JP2005535688A (ja) 2005-11-24
UA82322C2 (uk) 2008-04-10
EP2301551A1 (de) 2011-03-30
ES2369535T3 (es) 2011-12-01
WO2004012744A1 (de) 2004-02-12
EP1545553B1 (de) 2011-07-13
US20100190738A1 (en) 2010-07-29
PL375493A1 (en) 2005-11-28
CN1302780C (zh) 2007-03-07
NZ538428A (en) 2006-09-29
NO335196B1 (no) 2014-10-20
AR040717A1 (es) 2005-04-20
CY1111902T1 (el) 2015-11-04
AU2008203060A1 (en) 2008-07-31
ZA200500453B (en) 2005-08-31

Similar Documents

Publication Publication Date Title
HRP20050184B1 (hr) Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
ME00425B (me) Liječenje sa anti-vegf antitijelima
SE0101387D0 (sv) Novel compounds
YU21401A (sh) Tetrahidropiridoetri
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
CY1108715T1 (el) Νεες πυριδοπυραζινες και η χρηση τους ως διαμορφωτες kinασων
ME00017B (me) Derivati kamptotecina koji imaju antitumorno dejstvo
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
UY27511A1 (es) Nuevos agentes andidiabéticos
NO20050640L (no) Rutenium anticancer komplekser
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
NO20042035L (no) Forbedret anvendelse av antitumorforbindelse i kreftterapi
DE60013486D1 (de) Verbindungen
UY26895A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
PL1814879T3 (pl) Pochodne 4,7-dioksobenzotiazolo-2-karboksyamidu, ich wytwarzanie oraz ich zastosowania terapeutyczne
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ATE353648T1 (de) Benzothiazole derivate und ihre anwendung in der behandlung von adenosine a2a rezeptor vermittelte krankheiten
NO20055650D0 (no) Ruteinum (II)-komplekser for behandling av tumorer
BRPI0410998A (pt) derivados de indol com efeito de indução de apoptose
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ZENTARIS GMBH, DE

PNAN Change of the applicant name, address/residence

Owner name: ÆTERNA ZENTARIS GMBH, DE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160714

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20170729